Abstract
Oesophageal adenocarcinoma (OAC) has a poor prognosis, and chemoprevention is an attractive option to reduce the burden of the disease. Hydroxyl-methyl-CoA reductase inhibitors (statins) have been shown to exert potentially useful anticancer effects against OAC cell lines, but there are only limited clinical data examining the effects of statins on the incidence of OAC.
Original language | English |
---|---|
Pages (from-to) | 917-23 |
Number of pages | 7 |
Journal | European Journal of Gastroenterology & Hepatology |
Volume | 24 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2012 |
Keywords
- Adenocarcinoma
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents, Non-Steroidal
- Aspirin
- Barrett Esophagus
- Case-Control Studies
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Esophageal Neoplasms
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Incidence
- Male
- Middle Aged